Zepsun (donafenib) / Suzhou Zelgen 
Welcome,         Profile    Billing    Logout  
 0 Diseases   13 Trials   13 Trials   91 News 


«12345
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date, Metastases:  Donafenib for Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 6, 2020   
    P3,  N=510, Active, not recruiting, 
    Trial completion date: Apr 2020 --> Oct 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date:  A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) -  Oct 21, 2019   
    P3,  N=204, Recruiting, 
    Trial completion date: Apr 2020 --> Oct 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Trial completion date: Jun 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Dec 2020
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date, Metastases:  Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 21, 2019   
    P2/3,  N=668, Active, not recruiting, 
    Trial completion date: Jun 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Dec 2020 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Dec 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Mar 22, 2019   
    P1/2,  N=18, Recruiting, 
    Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Dec 2019 Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer (clinicaltrials.gov) -  Mar 22, 2019   
    P1b,  N=19, Recruiting, 
    Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer (clinicaltrials.gov) -  Mar 22, 2019   
    P1b,  N=17, Recruiting, 
    Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Donafenib for Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 4, 2019   
    P3,  N=510, Active, not recruiting, 
    Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Aug 2018 --> Dec 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion date, Trial primary completion date, Metastases:  Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 1, 2019   
    P2/3,  N=668, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Aug 2018 --> Dec 2019 Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Sep 2019
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion:  Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) -  Mar 1, 2019   
    P2,  N=48, Completed, 
    Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Sep 2019 Active, not recruiting --> Completed
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial primary completion date, Monotherapy, Metastases:  A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer (clinicaltrials.gov) -  Aug 3, 2018   
    P1b,  N=19, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment closed, Trial primary completion date:  Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) -  Aug 3, 2018   
    P2,  N=48, Active, not recruiting, 
    Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jul 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment closed, Metastases:  Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 3, 2018   
    P2/3,  N=668, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jul 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Phase classification, Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Oct 17, 2017   
    P1/2,  N=18, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial primary completion date, Monotherapy, Metastases:  A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer (clinicaltrials.gov) -  Oct 11, 2017   
    P1b,  N=19, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Sep 2017 --> Jun 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer (clinicaltrials.gov) -  Oct 10, 2017   
    P1b,  N=17, Recruiting, 
    Trial primary completion date: Sep 2017 --> Jun 2018 Trial primary completion date: Jul 2017 --> Jun 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Trial primary completion date:  Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) -  Oct 10, 2017   
    P2,  N=48, Recruiting, 
    Trial primary completion date: Jul 2017 --> Jun 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Dec 2017
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Donafenib for Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 22, 2017   
    P3,  N=510, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Aug 2018
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial initiation date, Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Oct 13, 2016   
    P1,  N=18, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Aug 2018 Initiation date: May 2016 --> Nov 2016 | Trial primary completion date: Aug 2017 --> Dec 2017
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Trial initiation date, Monotherapy, Metastases:  A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer (clinicaltrials.gov) -  Aug 15, 2016   
    P1b,  N=19, Recruiting, 
    Initiation date: May 2016 --> Nov 2016 | Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer (clinicaltrials.gov) -  Aug 15, 2016   
    P1b,  N=17, Recruiting, 
    Active, not recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open, Metastases:  Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 28, 2016   
    P2/3,  N=600, Recruiting, 
    Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Trial completion, Trial primary completion date, Monotherapy, Metastases:  Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 5, 2016   
    P1b,  N=47, Completed, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Oct 2015